Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Sanara Medtech, Inc. (SMTI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$32.33+0.50%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.58 → 0.58 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SMTI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Gross profit grows to support margin improvement | Gross profit improved by $4.3M, reflecting pricing and efficiency gains. | Intact | Gross profit falls below $22M in next 4 quarters | Gross profit: $26.155M FY2026-Q2; GAAP. Published target: Gross profit >= $25.9M next 4 quarters. Target period is not explicitly aligned with this observation. Aug 11, 202626,155,410 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented medical products business with recent financial performance described as strong and a Healthcare sector tailwind. Its long-term thesis is intact, though the overall signal has shifted from mildly favorable to mixed and earnings quality remains fragile.
The valuation model shows SMTI at a 1.0 premium versus peers, with expectations below the model by 17%; the valuation signal is described as aligned and the priced-in fragility tier is low. In plain terms, weak execution quality appears to be recognized, but the evidence does not show that the full combination of expensive valuation, weak execution, and turbulence is priced in.
Near-term revenue growth and gross margins have been progressing: Q2 revenue rose 9% year over year, year-to-date revenue rose 14%, and gross margin reached 93%. Operating income fell year over year in Q2 but improved year to date, while recent earnings misses and elevated risk of another miss leave execution uncertain; litigation filed in October is also a recent negative event.
The multi-year view depends on continued revenue growth from soft tissue repair products and market expansion, alongside better operating income despite higher selling, general, and administrative expenses. Near term, a guidance cut or further weak jobs data would be unfavorable, while continued strong results and guidance from Healthcare bellwethers could support sector momentum.
SMTI’s growth and margin progress support an intact 1-to-3-year thesis, but fragile earnings quality, recent misses, and elevated risk make execution the key issue. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “Gross margin was 93% of net revenue for the second quarter of 2026, compared to 92% of net revenue for the second quarter of 2025.” “Gross margin was 93% of net revenue for the first quarter of 2026, compared to 92% of net revenue for the first quarter of 2025.”
Operating income increases to sustain positive trajectory | Operating income rose from $0.8M to $2.6M, showing better cost control. | Intact | Operating income falls below $1.5M in next 4 quarters | Operating income: $1.78M FY2026-Q2; GAAP. Published target: Operating income >= $2.6M next 4 quarters. Target period is not explicitly aligned with this observation. Aug 11, 20261,780,377 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Increase revenue to about $118.5M in FY26 | A primary condition in Sanara Medtech, Inc.'s published investment case. The stated target is ~$118.5M. | Intact | Revenue falls below $110M in FY26 | Revenue: $28.137M FY2026-Q2; GAAP. Published target: ~$118.5M. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 202628,136,757 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Management Comments Seth Yon, President and Chief Executive Officer of Sanara, commented, We continued to drive solid revenue growth in the second quarter of 2026 with net revenue of $28.1 million, representing a 9% increase over the second quarter of 2025, as well as gross margin of 93% supporting Adjusted EBITDA of $5.0 million.” “With our visibility today, we remain confident in our full-year guidance of 13% to 17% net revenue growth,” Mr. Yon concluded.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.47 → $0.58 · observed estimates
$0.13B → $0.13B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-07-25 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-07-26 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-07-27 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-07-28 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-07-29 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-07-30 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-07-31 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-01 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-02 | $0.54 | $133,195,000 | 1 / 2 |
| 2026-08-03 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-04 | $0.54 | $133,195,000 | 1 / 2 |
| 2026-08-05 | $0.54 | $133,195,000 | 1 / 2 |
| 2026-08-06 | $0.54 | $133,195,000 | 1 / 2 |
| 2026-08-08 | $0.54 | $133,195,000 | 1 / 2 |
| 2026-08-09 | $0.54 | $133,195,000 | 1 / 2 |
| 2026-08-10 | $0.54 | $133,195,000 | 1 / 2 |
| 2026-08-12 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-13 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-14 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-15 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-16 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-17 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-18 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-19 | $0.47 | $133,000,000 | 1 / 2 |
| 2026-08-20 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-21 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-22 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-23 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-24 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-25 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-26 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-27 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-28 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-29 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-30 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-08-31 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-01 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-02 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-03 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-04 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-05 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-06 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-07 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-08 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-09 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-10 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-11 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-12 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-13 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-14 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-15 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-16 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-17 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-18 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-19 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-20 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-21 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-22 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-23 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-24 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-25 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-26 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-27 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-28 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-29 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-09-30 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-01 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-02 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-03 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-04 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-05 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-06 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-07 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-08 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-09 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-10 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-11 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-12 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-13 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-14 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-15 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-16 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-17 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-18 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-19 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-20 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-21 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-22 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-23 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-24 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-25 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-26 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-27 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-28 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-29 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-30 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-10-31 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-11-01 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-11-02 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-11-03 | $0.58 | $131,600,000 | 1 / 2 |
| 2026-11-04 | $0.58 | $131,600,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.